Partnering to Bring Meaningful Science to Patients

We are building partnerships that advance science with the urgency that today's global health challenges demand. Our collaborations, including in- and out-licensing, co-promotions, equity investments, divestitures, and M&A, are critical to who we are and how we work.

As we continuously look for new opportunities, we embrace the challenges of bringing these products to patients in a competitive business environment, working tirelessly to find the best solutions to improve the lives of the patients we serve.
In addition to industry partners, we also work with government agencies, early biotech companies and academia. Our public/private partnership with the NIH is helping to accelerate the global development program for our investigational oral antiviral for COVID-19.
Our investments in early stage biotechs, including Akili Interactive, HanaVax Inc. and InveniAI® LLC, and our academic research collaborations with Nagasaki University and Hokkaido University enable us to fund emerging science for new treatments in disease areas with unmet needs.
Our strengths lie in drug discovery and development, but also include industry-leading commercial capabilities which have been proven over our more than a century history. Our teams have expertise in discovery, development, production and commercializing products in virology, infectious disease, and respiratory and central nervous system disorders.
Today, we seek innovative collaborations that leverage our expertise in the following therapeutic areas:
  • Infectious Diseases & Hospital-Based Critical Care Therapies
  • Central Nervous System (CNS)
  • Rare & Orphan Conditions
Through a combination of in-house discovery and collaborations, we are delivering firsts for patients in the U.S. and around the world, as demonstrated through our track record of successful collaborations:

ViiV Healthcare

Alongside GlaxoSmithKline (GSK) and Pfizer, we are collaborating with ViiV Healthcare to produce vital medicines for treating and preventing HIV/AIDS. Our collaboration has produced several treatment options over the last decade, including dolutegravir and cabotegravir. Today, Shionogi continues to develop innovative HIV therapies.


Our collaboration with Duchesnay, a specialty pharma company focusing on women's health, provides for distribution and marketing of Osphena® (ospemifene), a compound developed by Shionogi, in the U.S. and Canada.

BioDelivery Sciences, Inc.

Our collaboration with BioDelivery Sciences Inc., a wholly owned subsidiary of Collegium, was structured as an out-licensing of Symproic® (naldemedine) in the U.S. Shionogi developed Symproic® for patients with opioid-induced constipation.


In a license and collaboration agreement with the Roche Group, we developed Xofluza® (baloxavir marboxil), an influenza medication, for Roche to commercialize in the U.S.

Contact Us

We look forward to hearing from you. Email us at